Beneficial Effects of Combined Benazepril-Amlodipine on Cardiac Nitric Oxide, cGMP, and TNF-α Production After Cardiac Ischemia
- 1 May 2006
- journal article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 47 (5) , 636-642
- https://doi.org/10.1097/01.fjc.0000211750.01326.b3
Abstract
The aim of this study was to determine if myocardial inflammation is increased after myocardial ischemia and whether angiotensin-converting enzyme inhibitors, calcium channel blockers, or diuretics decrease mediators of inflammation in rats with induced myocardial ischemia. Changes in cardiac interstitial fluid (CIF) levels of nitric oxide metabolites (NOX), cyclic guanosine 3′,5′-monophosphate (cGMP), angiotensin II (Ang II), and tumor necrosis factor-α (TNF-α) were monitored with/without oral administration of benazepril, amlodipine, combined benazepril-amlodipine, or hydrochlorothiazide. Using a microdialysis technique, levels of several mediators of inflammation were measured after sham operation or 30-minute occlusion of the left anterior descending coronary artery. Compared with sham animals, levels of CIF NOX and cGMP were decreased in animals with ischemia (P<0.001). Benazepril or amlodipine significantly increased NOX levels (P<0.05 vs. untreated ischemia), but only benazepril significantly increased cGMP (P<0.05). Combined benazepril-amlodipine further increased CIF NOX and cGMP (P<0.001), compared with either drug alone. CIF Ang II and TNF-α in sham animals did not change significantly. In animals with ischemia, CIF Ang II and TNF-α increased progressively. Amlodipine alone, benazepril alone, or combined benazepril-amlodipine significantly reduced TNF-α (P<0.01 for monotherapies and P<0.001 for combination therapy). Hydrochlorothiazide did not cause significant changes in NOX, cGMP, or TNF-α. Combination benazepril-amlodipine may be beneficial for managing cardiac ischemia.Keywords
This publication has 36 references indexed in Scilit:
- Putting the Brakes on Cardiac HypertrophyHypertension, 2005
- Angiotensin II and the EndotheliumHypertension, 2005
- Amlodipine decreases fibrosis and cardiac hypertrophy in spontaneously hypertensive rats: persistent effects after withdrawalLife Sciences, 2004
- Novel anti-inflammatory actions of amlodipine in a rat model of arteriosclerosis induced by long-term inhibition of nitric oxide synthesisAmerican Journal of Physiology-Heart and Circulatory Physiology, 2004
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2002
- Tissue Angiotensin and Pathobiology of Vascular DiseaseHypertension, 2001
- Amlodipine/benazepril: fixed dose combination therapy for hypertensionExpert Opinion on Pharmacotherapy, 2001
- Nifedipine inhibits activation of transcription factor NF-κBLife Sciences, 2000
- Is there a rationale for combining angiotensinconverting enzyme inhibitors and calcium antagonists in cardiovascular disease?American Heart Journal, 1997
- A Clinical Trial of the Angiotensin-Converting–Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial InfarctionNew England Journal of Medicine, 1995